Shire CEO Ornskov Touts Outcomes-Based Deals

Original post, click here
Share this...
Tweet about this on TwitterShare on FacebookShare on LinkedInEmail this to someoneShare on Google+Share on RedditPin on Pinterest

Biotech company Shire’s chief executive, Flemming Ornskov, says rare disease firms will continue to move toward outcomes-based payment systems, charging health systems only when therapies are shown to have worked.

The increasing demand for rare disease drugs, however, is doing little to help in the way of affordability, pharmaphorum reports.

In an effort to combat pricing woes, Shire has moved toward outcomes-based pricing models which depend on the drug’s performance.

“We are willing to follow patients for a long period of time and rethink what we should get as reimbursement based on outcome,” Ornskov says.

Click here to read more on pharmaphorum.